About NMDP/Be The Match
Your partner from patient diagnosis through treatment and recovery
The cell therapy landscape is rapidly evolving, and so too is our partnership with you.
The National Marrow Donor Program® (NMDP)/Be The Match® began as a registry of unrelated donors for patients who needed a hematopoietic cell transplant (HCT). Today, our services have grown to include support for all types of cellular therapy, including haploidentical and fully matched related donor HCT, cord blood HCT, and new cell and gene therapies.
In partnership with the foremost centers around the world, we’re leading transformative research through the CIBMTR®—our research collaboration with the Medical College of Wisconsin—to expand patient access to treatment and help you make data-driven clinical decisions.
Discover how we work together with you throughout the treatment journey: advocating tirelessly to remove barriers to consultation and treatment, connecting patients to the optimal cell therapy and driving research to expand treatment options for all patients.
Delivering Cell Therapy
The proven partner connecting you to the best available therapy for patients
Our goal is to provide every patient with the cell therapy they need, regardless of cell source. The NMDP/Be The Match has the unique ability to source and transport cells globally using our proven, expansive supply chain network.
Our 30+ years of experience in logistics and supply chain management enables us to successfully navigate disruptions, from natural disasters to geopolitical events to a worldwide pandemic.
Unrelated donor and cord blood transplants
Despite varying registry requirements, we provide a standardized, consistent experience for searching and ordering from the global network.
We’re continually investing in increasing Be The Match Registry® diversity, donor engagement and donor availability to expand treatment access for patients. We utilize data and research to support the search and graft source selection process for unrelated donors and cord blood units.
Through clinical trials, like 15-MMUD and ACCESS, we aim to establish a new role for mismatched unrelated donor transplants to expand access to transplants for diverse patients.
Related donor transplants
We can facilitate your patient’s haploidentical or fully matched related donor collection through Related Donor Services, helping to remove logistical and financial barriers to treatment. When we facilitate your patient’s related donor collection, your patient and U.S.-based donor both receive the full support and benefits we provide when we facilitate a transplant with an unrelated donor.
Emerging cell and gene therapies
Through Be The Match BioTherapies®, we partner with cell and gene therapy developers to empower the discovery, development and delivery of next-generation therapies, bridging the gap between pharmaceutical companies and providers.
We are also tracking outcomes data for leading pharmaceutical companies for therapies like CAR-T through the CIBMTR, providing insights about how the drugs work and which patients are best positioned to benefit from them.
A global leader in research and advancing the future of care
As the leader in transformative research and outcomes analysis through the CIBMTR, we design and support prospective and retrospective studies on emerging therapies, identify trends and provide tools to help you:
- Make optimal cell source selections
- Inform treatment strategies
- Improve outcomes
With data from our world-renowned outcomes database, we establish and update evidence-based standards of care and clinical guidelines. Along with transplant outcomes, our outcomes database includes data for all commercially available manufactured cell therapy products.
With continual focus on improving outcomes, strategic initiatives are underway to use CIBMTR data to develop outcome prediction tools that recommend mismatched donors, haploidentical donors, cord blood, or cell and gene therapy products based on likely outcomes.
Advocacy and Resources
A tireless advocate for patients and cellular therapy providers
Influencing health policy and driving coverage and reimbursement improvements
We collaborate with providers, payers and government officials to influence policy changes that improve access to care. For example, through the tireless work of our team, other industry leaders and volunteers from across the country, the Patient Access to Cellular Therapy (PACT) Act, also known as Section 108, was signed into law. The PACT Act improves Medicare transplant reimbursement. We’ve also worked to expand Medicare coverage to include sickle cell disease, myelofibrosis and multiple myeloma through national clinical studies facilitated by the CIBMTR.
Additionally, we teamed with other organizations and advocates on legislation passed into law that requires Medicaid to cover routine costs of care when a patient enrolls in a clinical trial for cancer and other severely debilitating conditions, like sickle cell disease.
Clearing pathways for more patients to receive cellular therapy
Through programs like HLA Today, we work with community hematologists/oncologists to drive early referrals to transplant centers and improve patient outcomes. Additionally, we develop consultation timing guidelines in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT).
Breaking down barriers for patients, caregivers and donors
Not every barrier in a patient’s road to treatment and recovery is related to their physical health. Sometimes it’s a patient’s psychosocial circumstances or financial health—like high out-of-pocket costs for lodging for the patient and caregiver before, during and after transplant.
We break down non-medical barriers patients, caregivers and donors face to ensure all patients receive the life-saving treatment they need.
Our dedicated Be The Match Foundation® team raises funds that enable us to:
- Add new potential donors to the Be The Match Registry®
- Conduct research to save more lives
- Provide millions of dollars in financial assistance for patients, donors and caregivers for expenses before, during, and after transplant
For patients and caregivers, we offer confidential support, including one-on-one guidance, a patient-friendly searchable clinical trials database, educational resources and more.
And, we’ve developed programs to engage registry members while they wait and improve availability when they’re called to donate.
Resources, continued education and training for your team